Aspen Pharmacare to pay £8 million after colluding to rip off NHS

pharmafile | August 14, 2019 | News story | Research and Development |  Addison’s disease, Aspen Pharmacare, CMA, NHS, pharma 

South African firm Aspen Pharmacare has agreed to pay £8 million to Britain’s NHS over a dispute about overpayment.

The Competition and Markets Authority (CMA) said the settlement follows an investigation into collusion between Aspen and rival firms to keep competitors to its Fludrocortisone 0.1 mg tablets off the market.

Aspen’s Fludrocortisone tablets are used to treat Addison’s disease, a rare hormonal disorder which affects the adrenal glands.

Advertisement

Aspen may also have to pay an additional £2.1 million in fines as part of a wider package, if the investigation concludes that the company broke the law. The CMA is also investigating the two other companies involved in the collusion.

Andrea Coscelli, the CMA’s chief executive, commented in suggesting it was “unacceptable for the NHS – and the taxpayers who fund it – to have to pay millions of pounds more than they should for this life-saving drug.”

Louis Goss

Related Content

NIHR chief scientific adviser visits Huddersfield health innovation campus

Professor Lucy Chappell, Chief Scientific Adviser to the Department of Health and Social Care and …

Pharma sees climate disruption as growing supply-chain risk

Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

Five Facts about NHS and primary care

1 Primary care is the front door to the NHS, but it extends well beyond …

The Gateway to Local Adoption Series

Latest content